Nautilus Biotechnology, Inc. (NAUT)
| Market Cap | 121.39M +41.1% |
| Revenue (ttm) | 190,000 |
| Net Income | -56.52M |
| EPS | -0.45 |
| Shares Out | 127.26M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 386,715 |
| Open | 1.0000 |
| Previous Close | 0.9994 |
| Day's Range | 0.9500 - 1.0200 |
| 52-Week Range | 0.6900 - 4.3100 |
| Beta | 0.87 |
| Analysts | Strong Buy |
| Price Target | 4.00 (+319.33%) |
| Est. Earnings | Oct 27, 2026 |
About NAUT
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for NAUT stock is "Strong Buy." The 12-month stock price target is $4.0, which is an increase of 319.33% from the latest price.
News
Nautilus Biotechnology files $300M mixed securities shelf
16:07 EDT Nautilus Biotechnology (NAUT) files $300M mixed securities shelf
Nautilus Biotechnology Registration statement: Registration filing
Nautilus Biotechnology filed a registration statement on September 11, 2026, providing details about a securities offering with the SEC.
Nautilus Biotechnology initiated with an Outperform at Leerink
Leerink initiated coverage of Nautilus Biotechnology (NAUT) with an Outperform rating and $4 price target
Nature Methods Publication Reveals Deep Insights into Functional Biology through First-of-its-Kind Quantification of Tau Proteoforms
First large-scale, single-molecule analysis of the tau proteoform landscape reveals unique disease-associated modifications, a new source of potential biomarkers and drug targets, and a method Nautilu...
Nautilus Biotechnology Earnings Call Transcript: Q2 2026
R&D focus has shifted to proteoform applications due to strong customer demand and technical progress, with first revenue recognized this quarter. Operating expenses declined, cash runway extends into 2028, and commercial ramp is expected as new assays and platform launches approach.
Nautilus Biotechnology Earnings release: Q2 2026
Nautilus Biotechnology released its Q2 2026 earnings on July 28, 2026, summarizing the period's financial results.
Nautilus Biotechnology Quarterly report: Q2 2026
Nautilus Biotechnology has published its Q2 2026 quarterly earnings report on July 28, 2026.
Nautilus Biotechnology Reports Second Quarter 2026 Financial Results
SEATTLE, July 28, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the seco...
Nautilus Biotechnology to Announce Second Quarter 2026 Financial Results on July 28, 2026
SEATTLE, July 08, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report ...
Nautilus Biotechnology Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and advisory votes on executive compensation and its frequency. All proposals passed, with annual Say on Pay votes approved. No questions were submitted during the Q&A session.
Nautilus Biotechnology Earnings Call Transcript: Q1 2026
Q1 2026 saw strong execution on commercialization plans, reduced operating expenses, and expanded early access engagement, with Baylor College of Medicine as a key customer. Cash runway extends through 2027, and oncology assay development is on track for later this year.
Nautilus Biotechnology Earnings release: Q1 2026
Nautilus Biotechnology released its Q1 2026 earnings on April 28, 2026, summarizing the period's financial results.
Nautilus Biotechnology Quarterly report: Q1 2026
Nautilus Biotechnology has published its Q1 2026 quarterly earnings report on April 28, 2026.
Nautilus Biotechnology Reports First Quarter 2026 Financial Results
SEATTLE, April 28, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the fir...
Nautilus Biotechnology Proxy statement: Proxy filing
Nautilus Biotechnology filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Nautilus Biotechnology Proxy statement: Proxy filing
Nautilus Biotechnology filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Nautilus Biotechnology Transcript: Investor Summit Virtual Conference
Proteomics remains a critical bottleneck in drug development, with current technologies lacking depth and reproducibility. A new platform leveraging iterative mapping and advanced software aims to transform protein analysis, with early applications in Alzheimer's and oncology, and a strong financial runway supporting commercialization through 2027.
Nautilus announces first customer of its Iterative Mapping Early Access Program
Nautilus Biotechnology (NAUT) announced Baylor College of Medicine as the first customer of Nautilus’ Iterative Mapping Early Access Program. Through a National Institutes of Health, or NIH, U01-funde...
Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform
• Baylor selects the Nautilus Voyager™ Platform, now available through Early Access Program, for development of a first-in-class computational multi-omics toolkit • NIH-funded project leverages collab...
Nautilus Biotechnology Transcript: TD Cowen 46th Annual Health Care Conference
A novel proteomics platform was showcased, offering unprecedented sensitivity and reproducibility for both broadscale and targeted protein analysis. Early access programs are underway, with commercial launch and expanded assay portfolio expected by next year.
Nautilus Biotechnology appoints Faust as Vice President of Sales
Nautilus Biotechnology (NAUT) announced the appointment of Amber Faust as Vice President of Sales. Faust joins Nautilus following the public debut of the Nautilus Voyager Platform.
Nautilus Biotechnology price target raised to $4 from $2.50 at Guggenheim
Guggenheim raised the firm’s price target on Nautilus Biotechnology (NAUT) to $4 from $2.50 and keeps a Buy rating on the shares. Every aspect of the Q4 report firms up…
Nautilus Biotechnology Earnings Call Transcript: Q4 2025
Q4 2025 saw major technical and commercial milestones, including the Voyager instrument debut and early access program launch. Operating expenses and cash burn declined year-over-year, with commercial launch and revenue ramp expected in 2027.
Nautilus Biotechnology Annual report: Q4 2025
Nautilus Biotechnology has published its Q4 2025 annual report on February 26, 2026.
Nautilus Biotechnology Earnings release: Q4 2025
Nautilus Biotechnology released its Q4 2025 earnings on February 26, 2026, summarizing the period's financial results.